{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.75","upperLimit":"67.61","value":"58.40"},{"groupId":"OG001","lowerLimit":"61.34","upperLimit":"79.17","value":"71.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"OS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Two-year OS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT if eligible. Patients with persistent testicular involvement after Block 1 receive testicular radiation during the Block 2.","id":"OG000","title":"Arm A (HR and IR Control)"},{"description":"Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT if eligible. Patients with persistent testicular involvement after Block 1 receive testicular radiation during the first block of blinatumomab.","id":"OG001","title":"Arm B (HR and IR Blinatumomab)"}],"paramType":"NUMBER","populationDescription":"HR and IR patients randomized per protocol prior to June 30, 2019. This is the cohort of patients who were included in the primary analysis addressing the primary objective on HR/IR patients. Of the total of 216 randomized HR/IR patients, 2 patients with randomization procedure errors and 6 patients randomized after June 30, 2019 were excluded.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from date of randomization","title":"Overall Survival (OS) of HR and IR Relapse Patients","type":"SECONDARY","unitOfMeasure":"percentage of participants"}